Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

I work in drug discovery, finding new cancer immune checkpoint inhibitors, like PD-1, PD-L1. My key question is how can we design a high throughput screen platform to speed this up? In recent years, biological drugs targeting PD-1, PD-L1 have made significant progress. While small molecule drugs are still in the early stages of development, we aim to develop small molecule drugs targeting PD-1, PD-L1.

Homogeneous time resolved fluorescence, HTIF, and the af-ah-ly-zer are two technologies with applications in PD-1, PD-L1 inhibitor screening. The solubility of small molecules and the buffer mismatch are the primary challenges in the current experiment.